Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 7/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | CASP6 | P55212 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1558734 | 0.85 | KDM4C (0.50) | MAPTALDH1A1CASP7CASP6KDM4E | |
| SCHEMBL30910165 | 0.85 | KDM4E (0.43) | PDE4DMAPTALDH1A1KDM4EPOLB | |
| SCHEMBL9912567 | 0.81 | ABCC8 (0.43) | PDE4DMAPTALDH1A1KDM4EPOLB | |
| SCHEMBL28020015 | 0.80 | MAPT (0.43) | MAPTALDH1A1CASP7CASP6NPC1 | |
| SCHEMBL13163054 | 0.78 | MAPT (0.49) | MAPTALDH1A1CASP7CASP6POLB | |
| SCHEMBL1559276 | 0.78 | MAPT (0.53) | MAPTALDH1A1CASP7CASP6NPC1 | |
| SCHEMBL19158730 | 0.76 | PDE4D (0.59) | PDE4DMAPTALDH1A1KDM4EPOLB | |
| SCHEMBL5416309 | 0.75 | PDE4D (0.50) | PDE4DMAPTALDH1A1CASP7CASP6 | |
| SCHEMBL31367819 | 0.75 | PDE4D (0.73) | PDE4DMAPTALDH1A1KDM4EPOLB | |
| SCHEMBL7814443 | 0.75 | PDE4D (0.58) | PDE4DMAPTALDH1A1KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025090758-A1 | AHR AGONISTS | ELI LILLY AND COMPANY (US) | 2025-05-01 | — | — | WO | disclosed |
| US-20240300951-A1 | Pyrazolopyridinone Compounds | BEIGENE LTD. (KY) | 2024-09-12 | — | — | US | disclosed |
| US-20240270751-A1 | Pyrazolopyridinone Compounds | BEIGENE LTD. (KY) | 2024-08-15 | — | — | US | disclosed |
| EP-4380936-A1 | PYRAZOLOPYRIDINONE COMPOUNDS | BeiGene, Ltd. (KY) | 2024-06-12 | — | — | EP | disclosed |
| WO-2023011456-A1 | PYRAZOLOPYRIDINONE COMPOUNDS | BEIGENE, LTD. (KY) | 2023-02-09 | — | — | WO | disclosed |
| US-20210171503-A1 | GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF | ORFAN BIOTECH SL (ES) | 2021-06-10 | — | — | US | disclosed |
| US-8933095-B2 | KAT II inhibitors | PFIZER INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-20140057938-A1 | KAT ll INHIBITORS | PFIZER INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-20120302599-A1 | KAT ll INHIBITORS | PFIZER INC | 2012-11-29 | — | — | US | disclosed |
| US-20100240656-A1 | COMPOUNDS AS HSP90 INHIBITORS | ORYZON GENOMICS, S.A. (ES) | 2010-09-23 | — | — | US | disclosed |
| EP-2183221-A1 | NEW COMPOUNDS AS HSP90 INHIBITORS | Crystax Pharmaceuticals S.L. (ES) | 2010-05-12 | — | — | EP | disclosed |
| WO-2009007399-A1 | NEW COMPOUNDS AS HSP90 INHIBITORS | CRYSTAX PHARMACEUTICALS, S.L. (ES) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140057938-A1 | KAT ll INHIBITORS | KAT2A, KAT7, KAT5 | PDE4D 4003/4885MAPT 126/4885ALDH1A1 3280/4885 |
| US-20240300951-A1 | Pyrazolopyridinone Compounds | NFATC1, CD4, PBK | PDE4D 1391/4885MAPT 4030/4885ALDH1A1 1296/4885 |
| US-20100240656-A1 | COMPOUNDS AS HSP90 INHIBITORS | HSP90AB1, HSP90AB2P, HSP90AA1 | PDE4D 3599/4885MAPT 1807/4885ALDH1A1 1875/4885 |
| US-20120302599-A1 | KAT ll INHIBITORS | KAT2A, KAT7, KAT5 | PDE4D 4003/4885MAPT 126/4885ALDH1A1 3280/4885 |
| US-20240270751-A1 | Pyrazolopyridinone Compounds | NFATC1, CD4, PBK | PDE4D 1391/4885MAPT 4030/4885ALDH1A1 1296/4885 |
| US-20210171503-A1 | GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF | PNPO, XDH, GLS | PDE4D 1614/4885MAPT 2376/4885ALDH1A1 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.